Thermo Fisher Scientific (TMO) Expected to Announce Earnings on Wednesday

Thermo Fisher Scientific (NYSE:TMO) is expected to be announcing its earnings results before the market opens on Wednesday, April 23rd. Analysts expect the company to announce earnings of $5.11 per share and revenue of $10.23 billion for the quarter. Thermo Fisher Scientific has set its FY 2025 guidance at 23.100-23.500 EPS.Investors interested in registering for the company’s conference call can do so using this link.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. On average, analysts expect Thermo Fisher Scientific to post $23 EPS for the current fiscal year and $26 EPS for the next fiscal year.

Thermo Fisher Scientific Price Performance

TMO stock opened at $426.11 on Monday. Thermo Fisher Scientific has a one year low of $409.85 and a one year high of $627.88. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $160.85 billion, a PE ratio of 25.78, a P/E/G ratio of 2.99 and a beta of 0.86. The firm has a 50-day moving average of $497.67 and a two-hundred day moving average of $532.62.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.40%. The ex-dividend date was Friday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s payout ratio is 10.41%.

Insider Activity

In related news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the sale, the executive vice president now owns 16,363 shares in the company, valued at $9,582,009.17. This represents a 1.80 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the sale, the senior vice president now owns 10,816 shares of the company’s stock, valued at $5,759,736.32. This trade represents a 25.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 23,900 shares of company stock valued at $13,106,062. Company insiders own 0.34% of the company’s stock.

Institutional Trading of Thermo Fisher Scientific

An institutional investor recently raised its position in Thermo Fisher Scientific stock. Revolve Wealth Partners LLC lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 491 shares of the medical research company’s stock after buying an additional 20 shares during the period. Revolve Wealth Partners LLC’s holdings in Thermo Fisher Scientific were worth $255,000 at the end of the most recent quarter. 89.23% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on TMO shares. Barclays dropped their price target on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 10th. Morgan Stanley raised their price target on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a research note on Friday, January 31st. Scotiabank lifted their price objective on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a research note on Monday, February 3rd. StockNews.com upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Finally, Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price target on the stock in a research report on Friday, January 10th. Four research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $642.67.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.